Introduction {#sec1_1}
============

Gallstone disease ranks amongst the most prevalent gastrointestinal disorders in the Western world with estimates as high as 20% in European and Northern American populations, with rising incidence rates to be expected owing to the obesity epidemic \[[@B1]\]. Common bile duct (CBD) stones are to be expected in an estimated 10-20% of individuals with symptomatic gallstone disease, of whom 0.2% are at risk of acute bacterial cholangitis \[[@B2],[@B3]\].

Acute bacterial cholangitis together with acute cholecystitis (both of whom may occur in concert in an individual) is a gastrointestinal emergency in the spectrum of acute biliary infection with high mortality rates and, thus, the need for straightforward diagnostic evaluation and immediate treatment initiation \[[@B4]\]. Acute cholangitis is characterized by acute inflammation and infection of the bile duct system with increased bacterial loads (biliary infection) and high intraductal pressure levels (biliary obstruction) favouring bacterial and endotoxin translocation into the vascular and lymphatic drainage (concept of cholangiovenous and cholangiolymphatic reflux, respectively). In conjunction with an increased permeability of the acutely inflamed biliary epithelium, the stage is set for potentially fatal complications such as biliary sepsis and hepatic abscess. The mere presence of bacteria in the biliary system, termed *bacterobilia*, is a sine qua non but by itself not sufficient to elicit cholangitis symptoms without coexistent obstruction due to effective antibacterial mechanical effects of bile flow and biliary immunoglobulin (Ig) A secretion protecting Kupffer cell function and integrity of biliary tight junctions \[[@B5]\]. The critical threshold of intrabiliary pressure above which biliary bacterial translocation into the systemic circulation occurs has been determined to be \>20 cm H~2~O (normal: 7-14 cm H~2~O) \[[@B6],[@B7]\]. As for biliary obstruction, the most frequent causes underlying mechanical cholestasis are (not mutually exclusive) choledocholithiasis as the leading cause, benign and malignant biliary stenosis, postoperative strictures, sclerosing cholangitis, and post-biliary instrumentation (table [1](#T1){ref-type="table"}).

Despite the basically wide spectrum of potential causes of biliary obstruction, choledocholithiasis ranks first by far, which has been partly explained by cholesterol (secondary) bile duct stones being colonized by a bacterial biofilm, the clinical virulence of which is potentiated by obstruction-induced mucosal inflammatory cytokine production \[[@B8],[@B9]\]. By contrast, primary bile duct stones result from biliary infection in the first place. In addition, there are several other risk factors associated with biliary infection such as recent infection elsewhere in the organism, advanced age \>70 years, and presence of diabetes mellitus \[[@B10]\].

Clinical Presentation and Diagnosis {#sec1_2}
===================================

The clinical presentation is prototypically characterized by the so-called Charcot\'s triad as of 1887 which comprises intermittent fever, right upper quadrant (RUQ) pain, and jaundice ('hepatic fever' as by Dr. Jean-Martin Charcot). In 1959, Reynolds expanded the description of acute cholangitis by adding lethargy/mental confusion and shock indicative of ongoing biliary sepsis, thus dubbed the Reynolds\' pentad \[[@B11]\]. However, an unequivocal diagnosis of acute cholangitis calls for confirmation of the underlying biliary source of the systemic infection, e.g. by aspiration of purulent bile during endoscopic retrograde cholangiography (ERC) representing the formal (albeit insensitive) gold standard. Since no non-invasive methods exist to obtain bile samples for analysis, in clinical practice the diagnosis relies on clinical findings, e.g. presence of the Charcot\'s triad, and additional laboratory assessment focusing on signs of systemic infection and cholestasis. Likewise, alternative diagnoses, e.g. other abdominal infectious foci with septic cholestasis, have to be adequately excluded. Of interest, in a prospective study assessing the diagnostic power of the Charcot triad only 22% of patients exhibiting suppurative bile fluids on surgical choledochotomy complied with all three Charcot criteria, thus indicating that its diagnostic utility remains suboptimal \[[@B12]\]. In general, Charcot\'s triad exhibits a high specificity while sensitivity is low. An estimated 90% of patients present with fever, and 60-70% are jaundiced. In an occasional patient, pain may be the only complaint, which, however, can also be lacking altogether especially in the elderly population \[[@B13],[@B14]\]. Early diagnosis and timely treatment initiation is critical for an individual patient\'s prognosis, which is particularly important in the elderly population with often atypical presentations and, thus, considerable delays in diagnosis.

The Tokyo Guidelines {#sec2_1}
--------------------

Against this background, in the Tokyo guidelines derived from an international meeting in 2006 and updated in 2013, much progress has been made in the definition and classification of acute cholangitis.

Figure [1](#F1){ref-type="fig"} depicts the clinical diagnosis of acute cholangitis beyond the (impractical) evidence of purulent bile and the (unreliable) presence of Charcot\'s triad to incorporate laboratory evidence of infection and cholestasis as well as (aetiology-oriented) imaging studies, evaluating for dilatation of the biliary system as a minimum requirement and, more specific, existence of biliary stones, strictures, and stents, for example. As for clinical presentation, and in extension of the Charcot criteria, the Tokyo guideline participants have proposed a valid clinical cholangitis suspicion as per two or more of the following findings: history of biliary disease, fever/chills, jaundice, and right upper or upper abdominal pain \[[@B15]\].

Imaging Studies {#sec2_2}
---------------

There are various modalities available for imaging of the biliary tract, all of which harbour different benefits and caveats, with the most powerful being endoscopic ultrasound (EUS) and magnetic resonance cholangiopancreatography (MRCP) (table [2](#T2){ref-type="table"}). For example, MRCP is purely non-invasive in nature but requires that the patient\'s condition is stable enough to be transported to the radiology department. However, as a first screening modality assessing for gallstone disease, bile duct diameter, and exclusion of other abdominal infectious sources and stone-related complications, transabdominal ultrasound still has its role as a first imaging test in the initial evaluation due to its wide availability, e.g. in the emergency ward, despite its low sensitivity in CBD stone detection ranging from 25 to 63% \[[@B16]\]. Yet, ultrasound has high diagnostic accuracy in the demonstration of biliary dilatation \[[@B17]\]. It has to be kept in mind, however, that a clear-cut definition of biliary dilatation is not available, although the Rome III criteria have proposed a normal bile duct diameter ≤ 8 mm \[[@B18]\]. MRCP has an accuracy of detecting CBD stones surpassing 90%, though, while there is a clinically significant weakness in the detection of small stone diameters \[[@B19],[@B20]\]. EUS is a minimally invasive endoscopic procedure superior to ERC in delineating malignant causes of cholestasis and is at least equal to ERC in terms of stone detection \[[@B21],[@B22]\]. Same-session EUS-guided ERC has also been reported and is a rational approach in prioritizing patients for ERC and, in addition, impacts on ERC strategy by a priori knowledge of the level of obstruction and its underlying cause \[[@B23]\]. As a consequence, overall ERC-related risks of aggravating acute biliary infection are reduced by a minimization of contrast media injection volumes, which might increase intrabiliary pressure levels to an extent high enough to cause reflux of purulent bile contents, and by an avoidance of inadvertent injection into undrainable biliary segments, e.g. in complex hilar strictures \[[@B24]\]. Computed tomography has its clinical value above all in unstable patients with high suspicion of underlying malignancy or suspicion of complicating hepatic abscesses. Aside from patients with severe cholangitis in which delays in biliary drainage due to imaging are inacceptable, it is recommended to conduct EUS if available, alternatively MRCP, prior to ERC with biliary drainage. In a meta-analysis of a pooled data set of 301 patients, the aggregated sensitivities of EUS and MRCP for CBD stone detection were 93 and 85%, whereas their specificities were 96 and 93%, respectively \[[@B25]\].

Severity Assessment and Risk Stratification {#sec2_3}
-------------------------------------------

There is a wide spectrum of disease courses in acute bacterial cholangitis, ranging from self-limiting to life-threatening with the need to tailor treatment accordingly. An estimated 70% of patients respond to medical treatment comprising supportive and antimicrobial therapy with potentially significant impact on timing and strategy of biliary drainage \[[@B26]\]. In the Tokyo guideline 2013 (TG13), criteria for severity assessment, i.e., the TG07 criteria which have been criticized mostly due to the differentiation of grade I and II severity only by observation, thus making it unsuitable for clinical purposes, have been refined and re-defined in order to allow categorization at initial diagnosis; however, prospective validation is lacking \[[@B27]\].

These revised assessment criteria define acute bacterial cholangitis (table [3](#T3){ref-type="table"}) as follows: grade III (severe): presence of organ dysfunction; grade II (moderate): risk of increased severity without early biliary drainage; and grade I (mild).

Treatment Algorithm {#sec1_3}
===================

Treatment is directed at the two main pathophysiologic components of acute cholangitis, i.e. biliary infection and obstruction; therefore, both systemic antibiotic treatment and biliary drainage remain the mainstay treatment options. In addition, appropriate supportive care has to be administered, in more severe cases in an intensive care setting with the option of providing adequate organ support if necessary.

Hospitalization is usually considered necessary even for patients with mild acute cholangitis, although an occasional patient, e.g. with recurrent episodes of minor cholangitis bouts after bilioenteric surgery, might be deemed suitable for outpatient management. Otherwise, mild or moderate cholangitis patients are treated in the general medical ward, while patients with severe disease indicators and/or significant comorbid conditions are to be admitted to the intensive care unit.

General Treatment Aspects and Supportive Care {#sec2_4}
---------------------------------------------

As soon as diagnosis and intravenous access are established, aggressive fluid and electrolyte replacement as well as, if appropriate, intravenous analgesics are to be administered to correct volume depletion and restitute blood pressure levels.

Antibiotic Treatment {#sec2_5}
--------------------

In the presence of regular biliary tract anatomy, bile fluid is sterile but might become infected by bacteria via the ampulla, e.g. after stone passage, sphincterotomy, and/or stent placement, or via the portal route with bacterial translocation through hepatic sinusoids and the space of Disse \[[@B28],[@B29]\]. Thus, most pathogens relevant to cholangitis initiation and perpetuation are derived from gastrointestinal microbiota including Gram-negative enteric bacteria and enterococci.

Administration of antibiotic agents should be initiated empirically as early as possible in any patient with a clinical suspicion of cholangitis, i.e., \<1 h if there are signs of septic shock (as outlined in the Surviving Sepsis Campaign guidelines \[[@B30]\]), otherwise \<4 h for definitive diagnostic studies, and in any event before drainage procedures are performed. There are several aspects to be considered in the selection of an appropriate antibiotic agent such as the potentially infecting bacteria, the severity of the disease and comorbidities, allergies, local susceptibility patterns, and the patient\'s history of antibiotic usage.

The Tokyo guideline working group has issued expert opinion-based recommendations concerning antibiotic usage in acute bacterial cholangitis \[[@B31]\]. The type and duration of antibiotic treatment is dictated by disease severity, clinical response, and microbial test results \[[@B32]\]. In community-acquired cases, empirical therapy with penicillin/β-lactamase inhibitor combinations, e.g. ampicillin/sulbactam (grade I, 2-3 days), or antipseudomonal active piperacillin/tazobactam (grade II + III, 5-7 days) represents an adequate regimen \[[@B31]\]. Third- or fourth-generation cephalosporins represent alternative broad-spectrum agents in more severe cases. In grade III community-acquired cholangitis within an intensive care setting inclusion of vancomycin is prudent for *Enterococcus* spp. coverage until culture results are available. Fluoroquinolones (only \< grade III) with or without metronidazole for anaerobic coverage (strongly recommended after bilioenteric surgery with high probability of *Clostridium* and *Bacteroides* spp.) or carbapenems are alternative considerations once first-choice regimens prove clinically ineffective. In such circumstances, the adequacy of biliary drainage should be critically reconsidered as well. The importance of the quality of biliary drainage is highlighted by another study demonstrating that, in the setting of successful ERC drainage ('source control'), the clinical results were the same after 3 versus 5 days of antibiotic treatment \[[@B33]\]. By contrast, in the presence of residual stones or ongoing biliary obstruction antimicrobial treatment should be extended until the resolution of the anatomical alteration. However, in cases with documented bacteraemia with endocarditis-prone Gram-positive cocci such as *Enterococcus* spp. or *Streptococcus* spp. continuation of antimicrobial therapy over 2 weeks appears reasonable, albeit there are no well-designed randomized controlled trials to support such a procedure.

By contrast, healthcare-associated cholangitis is complicated by a higher rate of polymicrobial infections and/or infections with resistant organisms including *Pseudomonas*, methicillin-resistant *Staphylococcus aureus* (MRSA), and vancomycin-resistant *Enterococci* (VRE). Therefore, empirical treatment of such infections should address *Pseudomonas* species and ESBL(extended-spectrum β-lactamase)-producing Gram-negative organisms \[[@B34]\]. Vancomycin is recommended in the presence of known colonization with Gram-positive bacteria such as MRSA and/or *Enterococcus* spp. or when these multidrug-resistant organisms are of concern. VRE should be addressed by linezolid or daptomycin in individuals with known colonization, vancomycin pretreatment, or if these organisms are common in the community. There appear to be aetiology-specific peculiarities to be considered as well, e.g. the notoriously high rate of *Candida* and *Enterococcus* isolates in the rising population of sclerosing cholangitis in critically ill patients (SC-CIP) (see also article by Kirchner and Ruemmele \[[@B35]\] in this issue) \[[@B36],[@B37]\].

If results of blood and biliary cultures become available, empirically initiated broad-spectrum antibiotic regimens should be changed to narrow-spectrum agents and, if feasible, to an oral route of administration. Concerning bile cultures, which have been reported to be positive in the range of 59-93%, the updated TG13 guideline recommends acquisition of bile samples for microbial testing at the beginning of any drainage procedure \[[@B38]\]. By contrast, the rate of positive blood cultures in the cholangitis population is about 21-71%, with most of these bacteraemic isolates generating no cardiac vegetations on normal valves or miliary abscesses. Since the results of blood cultures usually do not affect clinical management and outcomes, routine blood cultures remain a matter of controversy. Biliary penetration of a given antimicrobial agent has traditionally influenced the selection of the agents. However, there are laboratory and clinical data showing that secretion of antimicrobial agents into bile plummets to low to zero levels in the setting of biliary obstruction, thus calling into question the theoretical benefits of biliary secreted over non-secreted compounds \[[@B39],[@B40]\].

Endoscopic Treatment {#sec2_6}
--------------------

In the era before effective biliary drainage procedures (and more potent antibiotic agents) became available, the mortality of acute cholangitis approached 100% with conservative treatment only (by now declined to 2.7-10% \[[@B41]\]), highlighting the need for the removal of biliary obstruction as the source of ongoing infection in acute bacterial cholangitis. Biliary drainage can be achieved by a multitude of ways, e.g. ERC, percutaneous transhepatic cholangiography, EUS-guided drainage, or surgical drainage, with the third being the procedure of choice whenever feasible. There are various endoscopic transpapillary options available, including biliary stent or nasobiliary drain placement above the obstruction site ± sphincterotomy, all of which with their appropriate indications corresponding to disease severity and clinical context \[[@B42]\]. Stenting has an equal effectiveness as nasobiliary drainage; however, it is associated with improved patient comfort, while the nasobiliary tube has the potential advantage of repeated bile aspiration for microbiologic analysis, flushings, and cholangiographic evaluation \[[@B43]\]. Routine sphincterotomy with the added risks of haemorrhage and perforation is not universally indicated for stents \<10 French and/or nasobiliary drainage, representing the preferred approach in patients with septic and/or therapeutic coagulopathy. In patients where the precise levels of obstruction are not unequivocally identified by limited cholangiography, a stent ≥110 mm (usually 10 French unless tight hilar strictures are present) relieves biliary obstruction proximal to the left or right intrahepatic duct -- bilateral stenting is usually not necessary except if both sides have been contaminated by contrast media \[[@B44]\].

Nevertheless, the diagnostic yield of ERC in the detection of CBD stones has been reported to be as high as 95% \[[@B45]\]. However, this implies that small stones may be missed, and another set of studies investigating the diagnostic power of stone detection based on cholangiogram only reported false-negative rates in up to 13% of cases \[[@B46]\]. Therefore, regarding a technical perspective, early radiographs after careful and slow contrast injection appear mandatory to avoid contrast media overfilling (as well as inadvertent proximal stone advancement). Contrast injection may be preceded by aspiration of bile cultures and placing a hydrophilic guide wire deep along the fluoroscopically anticipated course of the bile duct in order to allow drainage of opacified parts of the biliary system at the end of the procedure. By contrast, cholangiography can be avoided altogether in an occasional patient with advanced cholangitis, with the level and nature of biliary obstruction being determined by EUS or MRCP \[[@B47]\]. Overall, endoscopic sphincterotomy and stone extraction have been reported to be successful in more than 90%, with adverse event rates close to 5% and mortality rates \<1% \[[@B48]\]. After failure of primary wire-guided biliary cannulation, precut (e.g. needle-knife) sphincterotomy, percutaneous transhepatic drainage procedure, or a combined percutaneous/endoscopic approach may become necessary; parallel to the increase in technical complexity, however, the complication rates for these more advanced techniques are much higher than for standard procedures \[[@B49]\]. In few centres, EUS-guided biliary drainage has been introduced as a viable alternative after failed ERC access \[[@B50],[@B51]\]. This approach requires further standardization and clinical trial validation, though.

Bile duct clearance from stones is usually performed with balloon extractor catheters and/or wire baskets. Especially in a clinical setting of acute biliary tract infection, however, larger stones may become impacted and, thus, more resistant to successful removal. Traditionally, fragmentation of large biliary stones that might become entrapped in impacted baskets requires the performance of mechanical lithotripsy or direct cholangioscopy with electrohydraulic lithotripsy \[[@B52],[@B53],[@B54],[@B55]\]. If complete duct clearance fails in the initial procedure or in the presence of grade III cholangitis, biliary decompression should include placement of a stent or nasobiliary drain in the first place. Especially in patients with severe cholangitis, it is recommended that the initial procedure should be limited to stenting in order to minimize the risk of worsening sepsis and time under conscious sedation and/or anaesthesia. After resolution of the critical episode, complete stone removal should be performed, in more complex cases also by means of direct cholangioscopy, with intraductal lithotripsy being reported to clear difficult extrahepatic biliary stones in 83-100% of patients \[[@B56],[@B57],[@B58],[@B59]\].

After resolution of the acute illness has been achieved, a definitive treatment for the cause of acute cholangitis to reduce the risk of future biliary complications, for the most part in the form of short-term elective laparoscopic cholecystectomy, has to be performed \[[@B60]\]. Endoscopic sphincterotomy and stone extraction without subsequent cholecystectomy may be appropriate in select surgical high-risk patients with significant comorbid conditions. However, biliary symptoms recur twice as commonly and mortality is significantly increased in patients whose gallbladder remains in situ, with a 5-year risk of biliary complications resulting in cholecystectomy in as much as 15% \[[@B61],[@B62],[@B63]\].

Figure [2](#F2){ref-type="fig"} summarizes the clinical management of acute bacterial cholangitis as recommended by the TG13 guidelines.

Conclusions {#sec1_4}
===========

Clinical diagnosis should be based on clinical findings and laboratory (inflammatory and cholestasis) markers as well as imaging studies to detect biliary dilation and its aetiology. Initiation of broad-spectrum antibiotics addressing the typical Gram-negative enteric bacteria spectrum and (early) biliary drainage including ERC with bile duct clearance and/or biliary stenting are the therapeutic mainstay options. Elective laparoscopic cholecystectomy in case of a gallbladder in situ is generally recommended after the resolution of cholangitis.
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![Diagnostic algorithm in acute bacterial cholangitis. ERC = Endoscopic retrograde cholangiography; WBC = white blood cell; CRP = C-reactive protein; AP = alkaline phosphatase; γGT = γ-glutamyltransferase; ASAT = aspartate aminotransferase; ALAT = alanine aminotransferase.](vim-0031-0166-g01){#F1}

![Clinical TG13 flowchart for the management of acute cholangitis (reprinted with permission from \[[@B65]\]).](vim-0031-0166-g02){#F2}

###### 

Potential causes of acute bacterial cholangitis (non-exhaustive selection)

  ------------------------------------------------------------------------------------------------
  Choledocholithiasis
  Congenital factors
  Post-operative factors (bile duct injury, bilio-enteric anastomosis strictures, sump syndrome)
  Inflammatory factors (parasitic infection, oriental cholangitis)
  Malignant strictures (bile duct, gallbladder, ampullary, pancreatic malignancy)
  Duodenal tumours
  Pancreatitis
  External compression, e.g. pericholecystic inflammatory changes, Mirizzi syndrome
  Papillary stenosis
  Duodenal diverticulum/Lemmel syndrome
  ------------------------------------------------------------------------------------------------

###### 

Relative benefits and drawbacks of different imaging tests in the setting of acute bacterial cholangitis (modified from \[[@B4]\])

                                       Abdominal ultrasound             EUS                                                             MRCP                                                                                                                            CT                                                                        ERCP
  ------------------------------------ -------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------
  Availability                         widely                           limited                                                         limited                                                                                                                         helical CT rare                                                           available
  Portability                          yes                              limited                                                         no                                                                                                                              no                                                                        limited
  Invasiveness                         no                               (minimally) invasive                                            no                                                                                                                              no                                                                        invasive
  Need for sedation                    no                               yes                                                             some patients                                                                                                                   no                                                                        yes
  Sensitivity of stone detection       low                              at least as good as ERCP                                        high                                                                                                                            high (best for helical CT)                                                gold standard in most studies
  Sensitivity of stricture detection   low                              good                                                            best non-invasive method                                                                                                        fair                                                                      excellent
  Sensitivity of tumour detection      low                              excellent                                                       good                                                                                                                            good                                                                      fair
  Advantages                           widely available, non-invasive   excellent for small stones, option for same-session with ERCP   accurate without radiation exposure                                                                                             widely available and accurate                                             therapeutic capability
  Disadvantages                        low sensitivity                  invasive character, poor delineation of intrahepatic ducts      contraindication in patients with implantable devices, poor detection of small stones, not portable, patient has to be stable   effects on renal function, poor detection of small stones, not portable   invasive, possible worsening of condition

EUS = Endoscopic ultrasound; MRCP = magnetic resonance cholangiopancreatography; CT = computed tomography; ERCP = endoscopic retrograde cholangiopancreatography.

###### 

TG13 severity assessment criteria for acute bacterial cholangitis (modified from \[[@B64]\])

  ----------------------------------------------------------------------------------------------------
  *Grade III (severe)* defined by onset of organ dysfunction in at least one of these organ systems:
  1\. Cardiovascular: hypotension requiring dopamine ≥ 5 μg/kg per min or any dose of norepinephrine
  2\. Neurological: disturbance of consciousness
  3\. Respiratory: PaO~2~/FiO~2~ ratio \< 300
  4\. Renal: oliguria, serum creatinine \> 2.0 mg/dl
  5\. Hepatic: PT-INR \> 1.5
  6\. Haematological: platelet count \< 100,000/mm^3^
  *Grade II (moderate)* defined by any two of the following:
  1\. Abnormal WBC count: (\>12,000/mm^3^; \<4,000/mm^3^)
  2\. High fever: ≥39°C
  3\. Age: ≥75 years old
  4\. Hyperbilirubinaemia: total bilirubin ≥ 5 mg/dl
  5\. Hypoalbuminaemia: lower limit of normal value × 0.7
  *Grade I (mild)* does not meet the criteria for grade III and grade II at diagnosis
  ----------------------------------------------------------------------------------------------------
